ISRCTN - ISRCTN77054547: The SPironolactone and ACEtazolamide (SPACE) trial in the prevention of acute mountain sickness

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Buddha Basnyat

ORCID ID

Contact details

Nepal International Clinic
Lal Durbar
GPO BOX 3596
Kathmandu
1
Nepal
rishibas@wlink.com.np

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

OXTREC 1

Study information

Scientific title

Acronym

SPACE

Study hypothesis

Acute Mountain Sickness (AMS) is like a hangover (headache, nausea and tiredness being prominent features) that may manifest at altitudes greater than 2600 m when people ascend too high too fast.

This is a study to ascertain the benefit of spironolactone (aldactone), a water pill, in the prevention of AMS which comprises of headache, nausea and tiredness at altitude greater than 2700 m. Acetazolamide (Diamox®) which we know works for the prevention of AMS will be compared with spironolactone and a placebo or a sugar pill.

Hypothesis:
Spironolactone will prevent AMS.

Ethics approval

Added 24/11/2008: OXTREC approval on 07/10/2008 for the study (031 07).

Study design

Randomised, double blind, placebo controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Acute mountain sickness

Intervention

This is a prospective three armed, double blind, randomised, placebo controlled trial. Computer generated randomisation of spironolatone, acetazolamide and placebo will be carried out. After consent is obtained, participants will receive a four days supply of either spironolactone 50 mg twice daily (bid), acetazolamide 250 mg bid or visually matched placebo bid. Trekkers will be enrolled in the study and baseline measurements done at Pheriche (4300 m) and reassessed after their arrival at the endpoint in Lobuje (5000 m). The reassessment will take place at least 36 hours to a maximum of 96 hours (4 days) after taking the study drug.

Assessments and measurements will be made in these areas prior to and after ascension on the study drug:
1. Lake Louise Questionnaire
2. Oxygen saturation via pulse oximetry

The approach to Everest Base Camp provides a unique study population for the following reasons:
1. Large numbers of recently arrived (non-acclimated) trekkers
2. Relatively homogenous population (gender, age, physical fitness, etc.) with relatively few pre-existing conditions
3. Linear population movement along the approach
4. Rapid and quantitatively large elevation change (about 700 m)

Data will also be collected on the demographics of the study population at the enrolment site. The study will not provide financial assistance in the event of the development of complications of being at high altitude.

Intervention type

Drug

Phase

Not Specified

Drug names

Spironolactone, acetazolamide

Primary outcome measures

Main outcome measure will be incidence of AMS measured by Lake Louise acute mountain sickness score (LLscore) greater than or equal to three with headache and at least one other symptom.

Outcomes will be measured at baseline (Pheriche 4300 m) and remeasured at Lobuje (5000 m). The reassessment will take place at least 36 hours to a maximum of 96 hours (four days) after taking the study drug.

Secondary outcome measures

1. Oxygen saturation measured by pulse oximeter
2. Severity of symptom (LLscore greater than five)
3. Incidence of headache and severity of headache

Outcomes will be measured at baseline (Pheriche 4300 m) and remeasured at Lobuje (5000 m). The reassessment will take place at least 36 hours to a maximum of 96 hours (four days) after taking the study drug.

Overall trial start date

10/10/2007

Overall trial end date

25/11/2007

Reason abandoned

Eligibility

Participant inclusion criteria

1. Healthy subjects between the ages of 18 and 65
2. Male or female
3. Non-Nepali
4. Without AMS or any concurrent illness
5. Not already taking acetazolamide or any other drug for the prevention of altitude illness

Subjects will be enrolled by study administrators en route directly to Everest Base Camp or Kala Patthar between the villages of Pheriche/Dingboche and Lobuje.

Participant type

Patient

Age group

Adult

Gender

Not Specified

Target number of participants

100 in each arm of the study

Participant exclusion criteria

1. Individuals not meeting inclusion criteria, including mild AMS (more than one mild symptom on the Lake Louise Questionnaire) or significantly depressed oxygen saturation (less than 75%)
2. Females known to be pregnant, or cannot exclude the possibility of being pregnant, or have missed menses by over seven days
3. Individuals with a known drug allergy to acetazolamide or other sulfa drugs
4. Individuals who are on Angiotensin-Converting Enzyme (ACE) inhibitors (like enalapril) or other diuretics like amiloride or triamterene, as concurrent administration with spironolactone can cause hyperkalemia
5. Individuals who have spent 24 hours at an altitude of 4500 metres/14,000 feet within the last nine days
6. Anyone known to have taken any of the following in the last two days:
6.1. Acetazolamide (Diamox®)
6.2. Steroids (dexamethasone, prednisone)
6.3. Theophylline
6.4. Diuretics (Lasix®)
7. Individuals who have a known intracranial space occupying lesion or a history of elevated intracranial pressure, (i.e. tumours, hydrocephalus, etc)
8. Lack of informed consent will obviously mandate exclusion

Recruitment start date

10/10/2007

Recruitment end date

25/11/2007

Locations

Countries of recruitment

Nepal

Trial participating centre

Nepal International Clinic
Kathmandu
1
Nepal

Sponsor information

Organisation

University of Oxford (UK)

Sponsor details

University Offices
Wellington Square
Oxford
0X1 2JD
United Kingdom
+44 (0)1865 270143
research.services@admin.ox.ac.uk